8 results about "Mitogen activate protein" patented technology

The invention relates to application of mitogen-activated protein kinase PiPmk1 in screening molecules for inhibiting formation of a phytophthora infestans infection structure. The invention finds that the molecular marker plays a key role in the development of a phytophthora infestans cyst bud tube and / or the formation of an infection structure, which indicates that the molecular marker has the potential of serving as a target for inhibiting phytophthora infestans infection, and a corresponding molecular screening method and a generative prediction model are further developed and utilized; rapid and accurate prediction and screening of phytophthora infestans infection inhibitory molecules are realized, the research and development period and cost are greatly shortened, and a new thought and a new method are provided for development of accurate targeted green pesticides.

The present application relates to a kind of Anoectochilus roxburghii 'Jianye' mitogen-activated protein kinase ArMAPK20, coding gene and application, the above-mentioned protein kinase ArMAPK20 includes the polypeptide with the amino acid sequence as shown in SEQ ID NO.2.This application also provides the nucleotide sequence SEQ ID NO.1 for encoding the above-mentioned protein.This application provides a theoretical basis for improving the ability of Anoectochilus roxburghii to resist stem rot by using genetic engineering technology, and has important application value.

Embodiments of the present disclosure pertain to methods of treating a cancer in a subject by administering to the subject a compound that inhibits interaction between octamer-binding transcription factor 4 (OCT4) and Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2), OCT4 and DNA-dependent protein kinase catalytic subunit (DNA-PKcs), or combinations thereof. Additional embodiments of the present disclosure pertain to the compounds of the present disclosure. Further embodiments of the present disclosure pertain to methods of inhibiting interaction between OCT4 and MAPKAPK2 and / or OCT4 and DNA-PKcs by exposing protein complexes to the compounds of the present disclosure. Additional embodiments of the present disclosure pertain to methods of screening potential inhibitors of protein-protein interaction between a first protein and a second protein.

Provided are compounds of Formula (I), a tautomer thereof, a deuterated derivative of the compound or the tautomer, and a pharmaceutically acceptable salt of the foregoing, compositions comprising the compounds of Formula (I), a tautomer thereof, a deuterated derivative of the compound or the tautomer, and / or a pharmaceutically acceptable salt of the foregoing, and methods of using the same, in treating, for example, the diseases, disorders, or conditions mediated by the degradation of protein kinases, such as Hematopoietic progenitor kinase 1 (HPK1, MAP4K1), Mitogen-activated protein kinases 1 / 2 (MEK 1 / 2), Human Fms-like tyrosine kinase 3 receptor (FLT3), and Aurora kinases.

A method for treating myopia is provided. Specifically, the method includes administering a mitogen-activated protein kinase (MAPK) signaling pathway inhibitor to a subject in need thereof. The inhibitor targets one or more kinases selected from MEK1, MEK2, ERK1, and ERK2, thereby modulating MAPK pathway activity to control ocular growth and progression of myopia.

Disclosed are neuronal mitogen-activated protein kinase interacting kinase (MNK) inhibitors and methods of using the same in treating a disease or disorder associated with MNK1 and / or MNK2 activity, such as a cancer or a cell proliferative disorder, or a central nervous system (CNS) disease.

The invention provides a protein composition for inhibiting inflammatory reaction, a plasmid and application thereof. The protein composition comprises listeriolysin O and mitogen activated protein kinase kinase 3; according to the construction method of the plasmid, an LLO gene, an NLRP3 gene and an MKK3 gene are taken as templates, and are respectively connected to an N-pCMV-Myc vector, an N-pCMV-HA vector and an N-pCMV-FLAG vector by using a homologous recombination method. The invention finds a new regulation channel for inhibiting inflammatory reaction when a host is infected by listeria monocytogenes, and finds that LLO can specifically bind MKK3 and NLRP3 by virtue of a bridge catalytic action, and then promotes degradation by virtue of a proteasome way, so that the inflammatory reaction of cells is inhibited. Under the discovery, the protein composition for inhibiting the inflammatory reaction, the plasmid and the construction method and application of the plasmid are prepared.

This invention discloses the application of compound 35C3 in inducing plant immunity and enhancing plant disease resistance, belonging to the field of biopesticide technology. Experiments have shown that compound 35C3 can effectively activate the phosphorylation of plant mitogen-activated protein kinase, induce reactive oxygen species (ROS) bursts, and upregulate the expression levels of disease resistance-related genes FRK1, PR1, PR2, WRKY29, and WRKY53. Pathogen inoculation experiments demonstrated that 35C3 can significantly enhance the resistance of Arabidopsis thaliana to *Pseudomonas syringae* and significantly enhance the resistance of poplar to *Colletotrichum gloeosporioides* and *Botrytis cinerea*. Its mechanism of action is to activate the plant's own immune system rather than directly inhibiting pathogen growth. Furthermore, 35C3 elicits immune responses in various crops, showing broad-spectrum applicability. This invention provides a new approach for developing environmentally friendly biopesticides and has significant agricultural application value.